Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/184378
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Millán, Olga | - |
dc.contributor.author | Rovira, Jordi | - |
dc.contributor.author | Guirado, Lluis | - |
dc.contributor.author | Espinosa, Cristina | - |
dc.contributor.author | Budde, Klemens | - |
dc.contributor.author | Sommerer, Claudia | - |
dc.contributor.author | Piñeiro, Gaston J. | - |
dc.contributor.author | Diekmann, Fritz | - |
dc.contributor.author | Brunet i Serra, Mercè | - |
dc.date.accessioned | 2022-03-24T08:14:17Z | - |
dc.date.available | 2022-03-24T08:14:17Z | - |
dc.date.issued | 2021-07-03 | - |
dc.identifier.issn | 1521-6616 | - |
dc.identifier.uri | http://hdl.handle.net/2445/184378 | - |
dc.description.abstract | This study evaluate the potential of plasmatic CXCL-10 (pCXCL-10) as a pre&post transplantation prognostic and diagnostic biomarker of T-cell-mediated rejection (TCMR), antibody-mediated rejection (ABMR) and subclinical rejection (SCR) risk in adult kidney recipients considering BKV and CMV infections as possible clinical confounder factors. Twenty-eight of 100 patients included experienced rejection (TCMR:14; ABMR:14); 8 SCR; 13 and 16 were diagnosed with BKV and CMV infection, respectively. Pre-transplantation pCXCL-10 was significantly increased in TCMR and ABMR and post-transplantation in TCMR, ABMR and SCR compared with nonrejectors. All CMV+ patients showed pCXCL-10 levels above the cutoff values established for rejection whereas the 80% of BKV+ patients showed pCXCL-10 concentration < 100 pg/mL. pCXCL-10 could improve pre-transplantation patient stratification and immunosuppressive treatment selection according to rejection risk; and after kidney transplantation could be a potential early prognostic biomarker for rejection. Clinical confounding factor in BKV+ and particularly in CMV+ patients must be discarded. | - |
dc.format.extent | 12 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Elsevier B.V. | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1016/j.clim.2021.108792 | - |
dc.relation.ispartof | Clinical Immunology, 2021, vol. 2029, num. 108792 | - |
dc.relation.uri | https://doi.org/10.1016/j.clim.2021.108792 | - |
dc.rights | cc-by-nc-nd (c) Millán, Olga et al., 2021 | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | - |
dc.source | Articles publicats en revistes (Medicina) | - |
dc.subject.classification | Trasplantament renal | - |
dc.subject.classification | Pronòstic mèdic | - |
dc.subject.classification | Rebuig (Biologia) | - |
dc.subject.other | Kidney transplantation | - |
dc.subject.other | Prognosis | - |
dc.subject.other | Graft rejection | - |
dc.title | Advantages of plasmatic CXCL-10 as a prognostic and diagnostic biomarker for the risk of rejection and subclinical rejection in kidney transplantation | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 718520 | - |
dc.date.updated | 2022-03-24T08:14:17Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 34217849 | - |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
718520.pdf | 2.32 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License